Drug Trial News

RSS

New drug sotatercept shows benefit in CpcPH-HFpEF patients

Patients who have heart failure with preserved ejection fraction (HFpEF) and high blood pressure in the lungs (pulmonary hypertension) experienced significant improvements in blood pressure and vascular health after taking the drug sotatercept, according to a study presented at the American College of Cardiology's Annual Scientific Session (ACC.26).

29 Mar 2026

Trial shows mavacamten benefits adolescents with obstructive heart condition

Adolescent patients with obstructive hypertrophic cardiomyopathy (HCM) who received the drug mavacamten saw a significant improvement in left ventricular outflow tract (LVOT) gradient, a measure of blood flow obstruction in the heart, compared with those who received a placebo, according to a small study presented at the American College of Cardiology's Annual Scientific Session (ACC.26).

29 Mar 2026

Intensive LDL cholesterol-lowering shows major benefits for heart disease patients

Using cholesterol-lowering medications more intensively to achieve a more aggressive target for low-density lipoprotein cholesterol (LDL-C) reduced the rate of major cardiovascular events by one-third among patients with atherosclerotic cardiovascular disease (ASCVD), according to a study presented at the American College of Cardiology's Annual Scientific Session (ACC.26).

28 Mar 2026

Evolocumab reduces cardiac events in high-risk diabetic patients

The cholesterol-lowering therapy evolocumab reduced the risk of major adverse cardiac events by nearly one-third among patients who had no known significant atherosclerosis and had diabetes, according to a study presented at the American College of Cardiology's Annual Scientific Session.

28 Mar 2026

Investigational drug lowers angiotensinogen but shows unclear blood pressure benefits

The investigational drug tonlamarsen—which is designed to lower blood pressure by reducing the production of angiotensinogen, a protein that turns into the hormone that regulates blood pressure—caused a significant and sustained drop in angiotensinogen but its impact on blood pressure was less clear, according to a study presented at the American College of Cardiology's Annual Scientific Session.

28 Mar 2026

Intensive cholesterol‑lowering therapy reduces first major cardiac event in high‑risk patients with diabetes

Mass General Brigham researchers found that the intensive cholesterol‑lowering therapy evolocumab reduced the risk of a first major cardiovascular event in high‑risk patients who did not have known atherosclerosis (the build-up of plaque inside artery walls) but did have diabetes.

28 Mar 2026

High-intensity therapy early after stroke shows no added benefit

A clinical trial led by University of Auckland researchers found that high-intensity therapy for patients begun within two weeks of a stroke did not improve hand and arm recovery beyond standard care.

26 Mar 2026

Immunotherapy plus chemotherapy improves outcomes in stage III dMMR colon cancer

A new study from researchers at the Alliance for Clinical Trials in Oncology (Alliance) shows that patients with stage III colon cancer with deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR) had significantly better outcomes when the immunotherapy drug atezolizumab (Tecentriq®) was added to standard chemotherapy after surgery.

25 Mar 2026

UT San Antonio study evaluates rapamycin’s potential to promote healthy aging

UT Health San Antonio, the academic health center of The University of Texas at San Antonio (UT San Antonio) is launching a multi-phase clinical study to better understand how the drug rapamycin may promote healthy aging.

25 Mar 2026

Experts propose trial to evaluate obesity medications for cancer prevention

In new research to be presented at this year's European Congress on Obesity (ECO2026) in Istanbul, Turkey (12-15 May), a global panel of 21 obesity and cancer experts suggest that to test the potential efficacy of the new generation of obesity drugs such as semaglutide and tirzepatide in preventing obesity-related cancer (ORC), a trial of the drugs for some 5,000 participants at high risk of cancer due to their having a cancer pre-cursor condition will provide the required answers.

25 Mar 2026

Massive clinical trial investigates brain training to delay dementia onset

An expansive clinical trial led by USF researchers and aimed at delaying the onset of dementia continues to receive major federal support for addressing a public health crisis.

25 Mar 2026

Major UK clinical trial finds surfactant therapy ineffective for severe bronchiolitis

A major UK-led clinical trial has found that a treatment commonly used to help premature babies breathe offers no benefit for infants on life support with severe bronchiolitis - a seasonal viral illness that hospitalizes thousands of babies each year.

23 Mar 2026

Oral semaglutide fails to slow early Alzheimer’s decline in two phase 3 trials

Two large phase 3 trials found that oral semaglutide 14 mg did not slow cognitive or functional decline over 104 weeks in people with early symptomatic, amyloid-positive Alzheimer’s disease. Semaglutide was generally consistent with its known safety profile and showed some biomarker changes, but these did not translate into clinical benefit.

22 Mar 2026

Combination therapy shows promise for leptomeningeal metastasis in breast cancer

Patients with leptomeningeal metastasis (LM) have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Center have found a combination of targeted therapies, tucatinib and trastuzumab, plus the chemotherapy drug, capecitabine, may improve symptoms and extend survival in some breast cancer patients with LM.

18 Mar 2026

Investigational oral therapy shows safety and potential benefits in ALS trial

In a phase 2b clinical trial, an investigational oral therapy called PrimeC was found to be safe and well tolerated in people living with amyotrophic lateral sclerosis (ALS), with exploratory findings suggesting target engagement and potential clinical benefits.

16 Mar 2026

Weekly buprenorphine injections improve opioid abstinence during pregnancy

In a clinical trial supported by the National Institutes of Health (NIH), a research team found that administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder (OUD) during pregnancy led to higher rates of abstinence from illicit opioids than buprenorphine given daily under the tongue (sublingual), one of the standard methods of treatment.

16 Mar 2026

Clinical trial tests a newer, targeted therapy for IDH mutant astrocytoma

A new clinical trial led by the Alliance for Clinical Trials in Oncology will investigate if a combination of drug therapies after radiation therapy improves outcomes for people with newly-diagnosed, grade 3 IDH-mutant astrocytoma, a type of brain cancer.

16 Mar 2026

Review examines clinical trial phases in drug development

Announcing a new article publication for BIO Integration journal. Clinical trials bridge basic research and clinical application, serving as essential steps in drug development.

13 Mar 2026

Romiplostim prevents chemotherapy-induced thrombocytopenia in phase 3 trial

Results from a global phase 3 clinical trial led by investigators at Mass General Brigham show that the medication romiplostim can effectively prevent chemotherapy from destroying platelet-producing bone marrow cells, a common complication known as chemotherapy-induced thrombocytopenia.

12 Mar 2026

High-dose vitamin D3 does not reduce COVID-19 severity, but may impact long COVID outcomes

In a large, randomized trial, researchers at Mass General Brigham have found that high-dose vitamin D3 did not reduce COVID-19 infection severity, but may impact long COVID outcomes.

12 Mar 2026